Michael Barbella, Managing Editor02.05.24
HeartBeam Inc. has added five cardiologists to its Scientific Advisory Board (SAB).
Formed in 2022, the SAB is led by HeartBeam Chief Medical Officer Peter J. Fitzgerald, M.D., Ph.D., and chaired by C. Michael Gibson, M.D. Fitzgerald is director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
Gibson is president/CEO of the Baim Institute for Clinical Research, Professor of Medicine, Harvard Medical School, and interventional cardiologist at Beth Israel Deaconess Medical Center. He is a cardiovascular researcher, and educator who pioneered understanding of the “open artery hypothesis” as well as understanding of the importance of restoring flow downstream in the capillary bed in the “open microvasculature hypothesis” in a heart attack.
The newly announced members of the HeartBeam SAB are:
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies.
Formed in 2022, the SAB is led by HeartBeam Chief Medical Officer Peter J. Fitzgerald, M.D., Ph.D., and chaired by C. Michael Gibson, M.D. Fitzgerald is director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
Gibson is president/CEO of the Baim Institute for Clinical Research, Professor of Medicine, Harvard Medical School, and interventional cardiologist at Beth Israel Deaconess Medical Center. He is a cardiovascular researcher, and educator who pioneered understanding of the “open artery hypothesis” as well as understanding of the importance of restoring flow downstream in the capillary bed in the “open microvasculature hypothesis” in a heart attack.
The newly announced members of the HeartBeam SAB are:
- Charles L. Brown III, M.D., CEO of the Piedmont Healthcare Physician Enterprise, which is comprised of Piedmont Heart, Piedmont Medical Care Corp., the Piedmont Clinic, and other clinical programs. Brown is responsible for all aspects of clinical services and care delivered by Piedmont’s Physician Enterprise. He is an interventional cardiologist who previously served as chief of Cardiovascular Services for the Piedmont Heart Institute.
- Tony Das, M.D., a nationally recognized board-certified interventional cardiology specialist, leader, and educator in cardiovascular diseases. Das founded Connected Cardiovascular Care in Dallas, the nation's first cardiology practice dedicated to individualizing each patient’s care with state-of-the-art remote digital monitoring technology. Das is chief of Strategic Planning and Development, and medical director of Digital Health, Innovation and Endovascular Services for Baylor Scott and White, The Heart Hospital Enterprise in Plano.
- Robert Harrington, M.D., dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. Harrington was previously chair of the Department of Medicine at Stanford University and is a past president of the American Heart Association. He is an accomplished cardiologist, with research areas of focus that include evaluating antithrombotic therapies to treat acute ischemic heart disease and trying to better understand and improve upon the methodology of clinical research.
- Campbell Rogers, M.D., executive vice president and chief medical officer at HeartFlow Inc. Rogers is an interventional cardiologist with a wealth of experience in research, teaching, and in industry. He previously served as chief scientific officer and global head of Research and Development at Cordis Corporation (Johnson & Johnson), associate professor of Medicine at Harvard Medical School, and director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital.
- Niraj Varma, M.D., Ph.D., professor of Medicine and consultant electrophysiologist at the Cleveland Clinic. Varma specializes in the treatment of heart arrhythmias, with interests in ablation for atrial fibrillation and ventricular tachycardia, defibrillator implantation, and biventricular pacing. He has led first clinical use of several novel technologies e.g., electrocardiographic imaging (ECGI), cardiac resynchronization algorithms, and cryoablation. Varma pioneered the application of remote monitoring of implantable devices, chairing the landmark TRUST randomized trial. The results have been pivotal and adopted widely to improve the care of patients receiving such cardiac devices worldwide. He has served on Heart Rhythm Society Scientific and clinical documents and Digital Health committees. Varma is past president of the International Society of Holter and Non-Invasive Electrocardiography. He has developed and chaired several professional society guidelines on remote monitoring over the last decade.
HeartBeam Inc. is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies.